HDT Bio Launches Canadian Phase 1 Trial of HDT-401, a Locally Administered RNA Immune Activator for Glioblastoma
核心洞察
HDT Bio has established HDT Bio Canada Inc. (搜索) and partnered with McGill University and The Neuro to advance HDT-401 into Phase 1 clinical evaluation for glioblastoma (搜索).
HDT-401 combines Riboxxim, a TLR3 (搜索)/RIG-I (搜索) agonist, with the LION™ lipid delivery platform to convert the glioblastoma (搜索) microenvironment from immune-suppressed to immune-engaged via local administration.
Encouraging compassionate use results informed the Phase 1 trial design, and a pre-CTA meeting with Health Canada has been completed with constructive feedback received.
HDT Bio Corp. (搜索) has announced the launch of a Canadian clinical program to evaluate HDT-401, an investigational locally administered RNA immune activator, in patients with glioblastoma (搜索). The Seattle-based clinical-stage biotechnology company has established HDT Bio Canada Inc. (搜索), its Montreal-based subsidiary, and partnered with McGill University and The Neuro (Montreal Neurological Institute-Hospital) (搜索) to advance the program into Phase 1 clinical testing.
The announcement, made July 12, 2026, marks a significant step for a disease that has seen virtually no improvement in decades. Glioblastoma (搜索) kills nearly everyone diagnosed, usually within 15 months, and the five-year survival rate remains below 5 percent. No approved immunotherapy has ever demonstrated a survival benefit in this indication.
A Novel Mechanism Targeting the Tumor Microenvironment
HDT-401 is designed to activate innate immune sensing directly within the tumor bed, converting the glioblastoma (搜索) microenvironment from immune-suppressed to immune-engaged. The approach aims to induce inflammatory cytokines, recruit immune effector cells, and support local immune recognition of tumor tissue. Local administration into the tumor or surgical cavity concentrates immune activation at the site of disease while limiting systemic exposure.
The investigational therapy combines two components: Riboxxim, a precisely engineered TLR3 (搜索)/RIG-I (搜索) agonist licensed from Dresden-based Riboxx GmbH (搜索), and HDT Bio's proprietary LION™ lipid delivery platform. The LION™ platform has been evaluated in more than 6,000 patients across multiple clinical programs, providing an extensive foundation of clinical experience.
"Riboxxim was engineered to solve a problem that earlier TLR3 (搜索) agonist technologies have never fully addressed: precise, reproducible immune activation without the unpredictability that limited clinical developments and market access," said Prof. Dr. Jacques Rohayem, CEO of Riboxx and the inventor of Riboxxim. "HDT Bio's approach of delivering Riboxxim is scientifically compelling because it concentrates immune activation exactly where it is needed most."
Compassionate Use Experience Informs Trial Design
HDT-401 has already been administered to glioblastoma (搜索) patients under compassionate use protocols. According to Steven Reed, PhD, Chief Executive Officer of HDT Bio Corp. (搜索), the results were encouraging enough to inform and shape the design of a formal Phase 1 clinical trial. "We have treated patients with HDT-401 under compassionate use. What we observed was encouraging. That is why we are moving as fast as we can to get this into a formal trial in Canada, with one of the world's great brain cancer research teams," Reed said.
HDT Bio Canada has completed a pre-Clinical Trial Application (CTA) meeting with Health Canada and received constructive feedback that advances the program toward CTA submission.
Clinical Leadership and Rationale
The planned Phase 1 study will be conducted in collaboration with Roberto Diaz, MD, PhD of The Neuro at McGill University, along with clinical and scientific experts across McGill-affiliated institutions in Montreal.
"Glioblastoma (搜索) remains one of the most difficult cancers to treat because recurrence is common and the tumor environment actively suppresses immune activity," said Dr. Diaz. "These are real patients with no good options. The tumor's ability to suppress immune activity locally is one of the central reasons it has resisted every treatment we have thrown at it. An approach that targets that immunosuppressive environment directly, at the tumor bed, is where the science points. That is why I am committed to this program."
Dr. Diaz also emphasized the surgical perspective: "When you operate on these patients, you understand the problem in a way that is difficult to convey. You resect what you can. You know what remains. And you know the current tools are not enough. This program is about changing that."
Canadian Manufacturing and Broader Commitment
HDT Bio is also advancing a breast cancer vaccine program in Canada, reflecting a broader commitment to Canadian patients and clinical infrastructure. For that program, the company has engaged Northern RNA Inc. (搜索) of Calgary as its Canadian GMP manufacturing partner.
"This is exactly the kind of program Northern RNA was built to support," said Jared Davis, President and CEO of Northern RNA Inc. (搜索) "Canadian patients with glioblastoma (搜索) deserve access to the most innovative treatments being developed anywhere in the world. Manufacturing in Canada, for Canadian patients, with a Canadian clinical partner, is how we help make that happen."
Disease Burden and Market Context
Glioblastoma (搜索) is the most common and aggressive primary malignant brain tumor in adults. Standard treatment includes maximal safe surgical resection, radiation therapy, and temozolomide chemotherapy, but recurrence is common and survival remains limited. Despite its devastating prognosis, glioblastoma receives significantly less research funding than other cancers of comparable lethality. The glioblastoma treatment market exceeds $3 billion annually and is projected to reach $4.46 billion by 2030.
HDT-401 has not been approved by Health Canada, the U.S. Food and Drug Administration, or any other regulatory authority.